

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



November 6, 2023

To whom it may concern:

Company name	KISSEI PHARMACEUTICAL CO., LTD.
Representative	Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takahide Kitahara, Managing Director, Department Manager of Corporate Finance and Management Department, CFO (Telephone +81-263-25-9081)

Notice concerning the Purchase of Treasury Shares through ToSTNeT-3

KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that its Board of Directors, at a meeting held today (November 6, 2023), decided on a specific method of acquisition of its own shares through the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3), which was resolved at the Board of Directors meeting held on May 8, 2023, pursuant to the provisions of Article 156 of the Companies Act after applying the provisions of Article 165, Paragraph 3 of the same Act as follows.

1. Method of acquisition

The Company will entrust the acquisition of its treasury shares at the closing price (including the final special quote) of 3,160 yen as of this day (November 6, 2023) through ToSTNeT-3 of the Tokyo Stock Exchange at 8:45 a.m. as of November 7, 2023 (no change to other trading systems and the trading time shall be made). In addition, such purchase order shall be valid only at the trading time mentioned above.

2. Details of the acquisition

- 1) Type of shares to be acquired: Common shares of the Company
- 2) Total number of shares to be acquired: Up to 1,200,000 shares
(Percentage of total number of issued shares (excluding treasury shares) : 2.62%)
- 3) Total acquisition cost: 3,792,000,000 yen (maximum)
- 4) Announcement of the results of the acquisition: The acquisition results shall be announced after the close of trading at 8:45 a.m. as of November 7, 2023.

Notes:1. The number of shares to be acquired as above shall not be changed. In addition, the whole or a part of the acquisition of the Company’s own shares may not be made according to the market conditions.

2. Acquisition of the Company’s own shares shall be made to sell orders matching buy orders.

(Reference)

1. Details of the resolution of the Board of Directors meeting held on May 8, 2023
 - 1) Type of shares to be acquired: Common shares of the Company

- 2) Total number of shares to be acquired: Up to 2,000,000 shares
(Percentage of total number of issued shares (excluding treasury shares) : 4.34%)
 - 3) Total acquisition cost: 6 billion yen (maximum)
 - 4) Acquisition period: From May 10, 2023 to March 29, 2024
 - 5) Acquisition method: Market purchases on the Tokyo Stock Exchange
 1. Purchases through the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
 2. Market purchases based on a discretionary trading contract regarding acquisition of own shares
-
2. Cumulative total of treasury shares repurchased in accordance with the resolution of the Board of Directors meeting held on May 8, 2023 (as of November 6, 2023)
 - Total number of shares acquired: 314,600 shares
 - Total amount of acquisition cost: 949,813,800 yen
-
3. Number of Treasury shares as of October 31, 2023
 - Total number of issued shares (excluding treasury shares): 45,800,913
 - Treasury shares: 3,510,272